ZYBT
Zhengye BiotechnologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Primary-source earnings context supports a real veterinary-vaccine operating business with 2025 regulatory approvals, progress on overseas registrations, a stated R&D and product-portfolio agenda, and year-end cash of RMB50.3 million despite the downturn [#PR-EARNINGS-2026-04-29].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.3.
What can break
Commercial payoff from new approvals, export registrations, R&D spending, and companion-animal expansion plans remains unproven in reported results [#PR-EARNINGS-2026-04-29].
Momentum
79
Value
57
Sentiment
45
Setup hits (3d)
— · Net —
AI TargetsBase $0.68 · Bull $1.15 · Bear $0.32
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Why
Momentum79 · Δ7d -
Value57 · Δ7d +0.3
Sentiment45 · Δ7d -
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
79
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-1.5
Sentiment
45
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 78.8 / Value 56.9 / Sentiment 44.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$20.75M
Beta
-
Shares Out
29.73M
P/E (TTM) · Derived
-3.4
P/S (TTM)
-
P/FCF (TTM) · Derived
19.18
Rev YoY
-
EPS YoY
-
Gross Margin
+20.4%
Op Margin
-
Net Debt
$3.32M
Current Ratio
1.14
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology